Evidence map›Paper›PMID 38093983›Full record

ArticleFrontiers in medicine2023

Insulin infusion sets associated with adverse events: strategies for improved diabetes education.

Ana Lucia Domingues Neves, Luiz Eduardo Galvão Martins, Mônica Andrade Lima Gabbay, Paula Pascali, Tiago de Oliveira, Aldo Martinazzo, Sérgio Atala Dib, Dulce Elena Casarini, Sebastião Vagner Aredes, Fernanda Silva Tenorio and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Ana Lucia Domingues NevesPostgraduate Program in Translational Medicine, Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Luiz Eduardo Galvão MartinsDepartment of Science and Technology, Institute of Science and Technology, Federal University of São Paulo, São Paulo, Brazil.
Mônica Andrade Lima GabbayDepartment of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Paula PascaliDiabetes Center Insulin Pump Ambulatory, Federal University of São Paulo, São Paulo, Brazil.
Tiago de OliveiraDepartment of Science and Technology, Institute of Science and Technology, Federal University of São Paulo, São Paulo, Brazil.
Aldo MartinazzoPostgraduate Program in Translational Medicine, Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Sérgio Atala DibDepartment of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Dulce Elena CasariniPostgraduate Program in Translational Medicine, Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Sebastião Vagner AredesDeltaLife, São José dos Campos, Brazil.
Fernanda Silva TenorioPostgraduate Program in Translational Medicine, Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil.
Tatiana Sousa CunhaDepartment of Science and Technology, Institute of Science and Technology, Federal University of São Paulo, São Paulo, Brazil.
Universidade Federal de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Insulin Infusion Sets (IIS) play a crucial role in ensuring the safe delivery of insulin through a Continuous Subcutaneous Insulin Infusion (CSII) for individuals with Type 1 Diabetes (T1D). Recent advancements in therapy have highlighted the need to address issues such as unexplained hyperglycemia and IIS occlusion. Objective: To investigate the adverse events (AEs) associated with IIS that impact the treatment of T1D, with a specific focus on promoting effective educational practices. Methods: One hundred and eighteen patients under treatment at the Diabetes Center Insulin Pump Ambulatory, Federal University of São Paulo responded to a semi-structured questionnaire. Over 6 months, a nurse researcher interviewed them via video calls. Results: Catheter-related adverse events (AEs) included catheter knots, folding, and accidental traction. AEs associated with cannula use were mainly related to cannula fixation adhesive, insulin leakage, bleeding episodes, and skin problems. The cannula patch tends to detach easily in hot conditions or when used for more than 3 days, leading to local itching. Adhesive glue can cause redness and pain. Insulin leakage typically occurs after the catheter disconnects from the cannula, accidental cannula traction, or beneath the cannula patch. Bleeding has been reported inside the cannula or at the insertion site, resulting in local pain and, in some cases, obstruction of insulin flow. When accidental cannula traction occurs, it is recommended to replace the entire IIS system. In situations involving bleeding, leakage, insulin odor, or unsuccessful attempts to correct hyperglycemic episodes with a "bolus" of insulin, it is advisable to change the IIS system and evaluate appropriate techniques for handling and infusing the device. Moreover, regular inspections of the device and reservoir/cartridge are essential. Conclusion: Serious AEs can occur even in cases where the occlusion alarm is not activated, leading to interruptions in insulin flow. Conversely, in less severe situations, alarm activation can occur even in the absence of insulin flow interruption. Accidental catheter traction and catheter bending are commonly encountered in everyday situations, while issues related to the cannula directly affect blood glucose levels. AEs related to the IIS cannula often involve insulin leakage into the skin, bleeding, and skin events attributed to adhesive issues with the cannula.

Indexed as

cannulacathetersdiabetes mellitus, type 1insulin infusion systemtechnology

Identifiers

PMID38093983
PMCPMC10716844
OpenAlexW4389141635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.